MA49617A - Analogues d'egf(a), préparation, formulations et utilisations associées - Google Patents

Analogues d'egf(a), préparation, formulations et utilisations associées

Info

Publication number
MA49617A
MA49617A MA049617A MA49617A MA49617A MA 49617 A MA49617 A MA 49617A MA 049617 A MA049617 A MA 049617A MA 49617 A MA49617 A MA 49617A MA 49617 A MA49617 A MA 49617A
Authority
MA
Morocco
Prior art keywords
egf
analogues
formulations
preparation
related uses
Prior art date
Application number
MA049617A
Other languages
English (en)
Inventor
Kim Vilbour Andersen
Florian Dismer
Jesper F Lau
Bhavesh Premdjee
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA49617A publication Critical patent/MA49617A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA049617A 2017-07-19 2018-07-19 Analogues d'egf(a), préparation, formulations et utilisations associées MA49617A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17182011 2017-07-19

Publications (1)

Publication Number Publication Date
MA49617A true MA49617A (fr) 2020-05-27

Family

ID=59383424

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049617A MA49617A (fr) 2017-07-19 2018-07-19 Analogues d'egf(a), préparation, formulations et utilisations associées

Country Status (6)

Country Link
US (1) US20200165313A1 (fr)
EP (1) EP3655426A1 (fr)
JP (1) JP2020527159A (fr)
CN (1) CN111164098A (fr)
MA (1) MA49617A (fr)
WO (1) WO2019016300A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3402811T3 (pl) 2016-01-13 2022-07-11 Novo Nordisk A/S Analogi egf(a) z podstawnikami kwasu tłuszczowego
AR112760A1 (es) 2017-07-19 2019-12-11 Novo Nordisk As Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a)
US20220323544A1 (en) 2019-08-07 2022-10-13 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
JP2002537321A (ja) 1999-02-22 2002-11-05 エラン コーポレイション ピーエルスィー 促進剤を含む固体経口剤形
US20090111730A1 (en) 2004-07-08 2009-04-30 Novo Nordisk A/S Polypeptide protracting tags
JP5021033B2 (ja) 2006-09-07 2012-09-05 エフ．ホフマン−ラ ロシュ アーゲー Ｓｎａｃ（サルカプロザートナトリウム）の製造法
EP2398822B1 (fr) 2009-02-19 2013-01-02 Novo Nordisk A/S Modification du facteur viii
CA2837658A1 (fr) 2011-06-20 2012-12-27 Genentech, Inc. Polypeptides liant pcsk9 et leurs procedes d'utilisation
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
PL3402811T3 (pl) * 2016-01-13 2022-07-11 Novo Nordisk A/S Analogi egf(a) z podstawnikami kwasu tłuszczowego

Also Published As

Publication number Publication date
CN111164098A (zh) 2020-05-15
JP2020527159A (ja) 2020-09-03
US20200165313A1 (en) 2020-05-28
EP3655426A1 (fr) 2020-05-27
WO2019016300A1 (fr) 2019-01-24

Similar Documents

Publication Publication Date Title
EP3893871C0 (fr) Dérivés de benzimidazolone, et analogues de ceux-ci, en tant que modulateurs d'il-17
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA51287A (fr) Analogues d'incrétine et leurs utilisations
GB2584341B (en) Cannabinoid formulations
SG10201808151RA (en) Cortistatin analogues and syntheses and uses thereof
BR112017006137A2 (pt) formulação que contém biotensoativo
UA42295S (uk) Комп'ютер
EP3615079A4 (fr) Formulations de cannabinoïdes stables
ZA202109070B (en) Imatinib formulations, manufacture, and uses thereof
MA49617A (fr) Analogues d'egf(a), préparation, formulations et utilisations associées
IL281362A (en) Formulations of glucagon-like peptide-2 (GLP-2) analogs
UA42369S (uk) Комп'ютер
MA54244A (fr) Vecteurs végétaux, compositions et utilisations associées
MA50047A (fr) Administration orale d'analogues peptidiques de glp-1
IL283395A (en) Arylmethylureas and substituted heteroarylmethylureas, their analogues and their uses
ZA202001756B (en) Oral care compositions
GEP20237486B (en) Formulations of copanlisib
EP3940136A4 (fr) Tringle pour dispositif d'agitation de vêtement, dispositif d'agitation de vêtement et équipement d'entretien de vêtement
MX2018007231A (es) Una composicion antimicrobiana.
EP3595693A4 (fr) Formulations et dosage de cannabinoïdes
MX2018009948A (es) Formulaciones de oritavancina.
IN2014KO00357A (fr)
MA56506A (fr) Promédicamentà base de succinate, compositions contenant le promédicament de succinate et utilisations associées